{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:49:40Z","timestamp":1785253780987,"version":"3.55.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ypmed.2016.11.029","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T11:45:43Z","timestamp":1486381543000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm"],"prefix":"10.1016","volume":"98","author":[{"given":"Joseph E.","family":"Tota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Coutl\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ire A.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ferenczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fung-Kee-Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Gotlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Mayrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"McLachlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Ratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2016.11.029_bb0005","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/jwh.2011.3385","article-title":"Cervical cancer trends in the United States: a 35-year population-based analysis","volume":"21","author":"Adegoke","year":"2012","journal-title":"J. Women's Health"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1158\/1055-9965.EPI-14-1417","article-title":"Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program","volume":"24","author":"Arbyn","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis","volume":"111","author":"Arbyn","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0020","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","article-title":"Trends of cervical cancer mortality in the member states of the European Union","volume":"45","author":"Arbyn","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","article-title":"Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis","volume":"15","author":"Arbyn","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/ijc.25144","article-title":"Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection","volume":"127","author":"Belinson","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0035","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25211","article-title":"The health and economic effects of HPV DNA screening in The Netherlands","volume":"127","author":"Berkhof","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncy.21544","article-title":"Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices","volume":"123","author":"Blatt","year":"2015","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0045","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0050","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0055","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0060","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2012.94","article-title":"Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway","volume":"106","author":"Burger","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1503\/cmaj.121505","article-title":"Recommendations on screening for cervical cancer","volume":"185","author":"Canadian Task Force on Preventive Health, C","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0070","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1309\/84E5WHJQHK83BGQD","article-title":"Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting","volume":"124","author":"Carozzi","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djj067","article-title":"Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention","volume":"98","author":"Castellsague","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0080","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/cncy.21572","article-title":"Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices","volume":"123","author":"Castle","year":"2015","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0085","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/JCM.40.3.1088-1090.2002","article-title":"Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible","volume":"40","author":"Castle","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/lgt.0b013e31815ea58b","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"12","author":"Castle","year":"2008","journal-title":"J. Low. Genit. Tract Dis."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0095","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0100","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1136\/bmj.e670","article-title":"Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model","volume":"344","author":"de Kok","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0105","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0110","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0115","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2012.10.006","article-title":"Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort","volume":"128","author":"Elit","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ypmed.2016.11.029_bb0130","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcv.2015.11.020","article-title":"Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none","volume":"76","author":"El-Zein","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10552-010-9694-3","article-title":"HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico","volume":"22","author":"Flores","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"Suppl. 1","key":"10.1016\/j.ypmed.2016.11.029_bb0140","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1016\/j.vaccine.2007.11.069","article-title":"Cervical cancer screening following prophylactic human papillomavirus vaccination","volume":"26","author":"Franco","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.ypmed.2016.11.029_bb0145","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.vaccine.2006.05.061","article-title":"Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination","volume":"24","author":"Franco","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change","volume":"40","author":"Franco","year":"2009","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0155","first-page":"106","article-title":"Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test","author":"Gage","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0160","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0165","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40258-014-0135-4","article-title":"Cost effectiveness of human papillomavirus-16\/18 genotyping in cervical cancer screening","volume":"13","author":"Huh","year":"2015","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"11","key":"10.1016\/j.ypmed.2016.11.029_bb0175","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/ijc.30385","article-title":"Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial","volume":"139","author":"Isidean","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1309\/QEJBYT77YMTEVJ66","article-title":"Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing","volume":"125","author":"Jastania","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009584","article-title":"Declining death rates reflect progress against cancer","volume":"5","author":"Jemal","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0190","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0195","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(09)70253-0","article-title":"Risk estimation for the next generation of prevention programmes for cervical cancer","volume":"10","author":"Katki","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0210","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","article-title":"Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low. Genit. Tract Dis."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3747\/co.22.2539","article-title":"Canadian cancer screening disparities: a recent historical perspective","volume":"22","author":"Kerner","year":"2015","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/AOG.0000000000000632","article-title":"Increased cervical cancer risk associated with screening at longer intervals","volume":"125","author":"Kinney","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0225","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","article-title":"HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial","volume":"10","author":"Kitchener","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0230","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0235","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/S0140-6736(11)61522-5","article-title":"Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial","volume":"378","author":"Lazcano-Ponce","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.28639","article-title":"Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women","volume":"135","author":"Lazcano-Ponce","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0250","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MLR.0b013e3181d6886f","article-title":"Low rates of cervical cancer screening among urban immigrants: a population-based study in Ontario, Canada","volume":"48","author":"Lofters","year":"2010","journal-title":"Med. Care"},{"issue":"474","key":"10.1016\/j.ypmed.2016.11.029_bb0255","first-page":"e1","article-title":"HPV testing with cytology triage for cervical cancer screening in routine practice","volume":"210","author":"Louvanto","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0260","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0265","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer","volume":"357","author":"Mayrand","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0270","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0275","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/bjc.1995.172","article-title":"Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit","volume":"71","author":"Mitchell","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0280","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0285","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0290","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0295","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0300","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nygard","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0310","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/bjc.2012.489","article-title":"Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial \u2014 the HPV FOCAL Study","volume":"107","author":"Ogilvie","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0315","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/ijc.29508","article-title":"Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis","volume":"137","author":"Ogilvie","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ypmed.2016.11.029_bb0320","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.30454","article-title":"HPV for Cervical cancer screening (HPV FOCAL): complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer","volume":"140","author":"Ogilvie","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0325","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/bjc.2015.474","article-title":"HPV immunisation and cervical screening-confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study","volume":"114","author":"Palmer","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0330","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0335","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.3747\/co.23.2991","article-title":"Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada","volume":"23","author":"Popadiuk","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0340","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1007\/BF03405681","article-title":"Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis","volume":"104","author":"Racey","year":"2013","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0345","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/eog.11.13","article-title":"Optimizing technology for cervical cancer screening","volume":"6","author":"Richardson","year":"2011","journal-title":"Expert Rev. Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0350","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.39196.740995.BE","article-title":"Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial","volume":"335","author":"Ronco","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0355","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(09)70360-2","article-title":"Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial","volume":"11","author":"Ronco","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0360","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0365","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0370","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0375","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ijc.24410","article-title":"Screening and adenocarcinoma of the cervix","volume":"125","author":"Sasieni","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0380","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3322\/canjclin.52.6.342","article-title":"American Cancer Society guideline for the early detection of cervical neoplasia and cancer","volume":"52","author":"Saslow","year":"2002","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0385","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0390","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0395","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/djq562","article-title":"Human papillomavirus testing in the prevention of cervical cancer","volume":"103","author":"Schiffman","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0400","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect. Agents Cancer"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0405","first-page":"1038","article-title":"Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions","volume":"12","author":"Sherman","year":"2003","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0410","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2009.1569","article-title":"Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial","volume":"302","author":"Siebers","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0415","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1186\/1471-2458-14-1060","article-title":"Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program","volume":"14","author":"Smith","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0420","first-page":"16","article-title":"Successes and challenges in population-based cancer screening","author":"Spayne","year":"2015","journal-title":"Healthc. Q."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ypmed.2007.06.007","article-title":"Process of care failures in invasive cervical cancer: systematic review and meta-analysis","volume":"45","author":"Spence","year":"2007","journal-title":"Prev. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0430","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1071\/SH10022","article-title":"Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era","volume":"7","author":"Tota","year":"2010","journal-title":"Sex. Health"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0435","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/aje\/kwt018","article-title":"Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination","volume":"178","author":"Tota","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0440","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.3747\/co.21.1720","article-title":"The road ahead for cervical cancer prevention and control","volume":"21","author":"Tota","year":"2014","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ypmed.2016.11.030","article-title":"Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening","volume":"98","author":"Tota","year":"2017","journal-title":"Prev. Med."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0450","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1470-2045(14)70019-1","article-title":"Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial","volume":"15","author":"Verhoef","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0455","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"von Karsa","year":"2015","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0465","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.vaccine.2014.12.002","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014-recommendations","volume":"33","author":"World Health Organization","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results","volume":"206","author":"Wright","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0475","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ypmed.2016.11.029_bb0480","first-page":"e95","article-title":"The budget impact of cervical cancer screening using HPV primary screening","volume":"22","author":"Wright","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0485","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.2105\/AJPH.90.9.1466","article-title":"Monitoring disease burden and preventive behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada","volume":"90","author":"Young","year":"2000","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ypmed.2016.11.029_bb0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncy.21687","article-title":"Clinical performance of the Food and Drug Administration-approved high-risk HPV test for the detection of high-grade cervicovaginal lesions","volume":"124","author":"Zhou","year":"2016","journal-title":"Cancer Cytopathol."}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743516303851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743516303851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T16:28:53Z","timestamp":1570465733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743516303851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":98,"alternative-id":["S0091743516303851"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2016.11.029","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2016.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}